510(k) device
Elecsys Tg II
Roche Diagnostics · System, Test, Thyroglobulin (MSW, Class II) · First FDA decision Sep 30, 2023, newest Sep 30, 2023Thyroid nodules and thyroid disease
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
0
Naming "Elecsys Tg II"
MAUDE reports
5
Brand "Elecsys Tg II", since 2015
PubMed studies
5
Mentioning "Elecsys Tg II"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Elecsys Tg II
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Elecsys Tg II510(k)
K221890 · Decided Sep 30, 2023 · 458 days after receipt
Device type: System, Test, Thyroglobulin (MSW) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Elecsys Tg II", any status and sponsor, newest update first.
No registered device study names "Elecsys Tg II".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Elecsys Tg II", and for the whole product code for context.
This brand
5 reports: 4 malfunction, 0 injury, 0 death
Whole product code MSW
82 reports: 75 malfunction, 6 injury, 0 death
Newest reports for this brand
- Elecsys Tg IIOther
1823260-2026-04507 · Received Oct 29, 2026
Device type: System, Test, Thyroglobulin (MSW)
Device problem as coded: Incorrect Measurement; High Test Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Elecsys Tg II"[tiab]. The summary above synthesizes these.
- Thyroglobulin Cutoff Values for Detecting Excellent Response to Therapy in Patients With Differentiated Thyroid Cancer.
Sipos JA, Aloi J, Gianoukakis A, et al. · J Endocr Soc · 2023
- Evaluation of a new automated assay for high-sensitivity thyroglobulin measurement and comparison with two established high-sensitivity thyroglobulin assays.
Broecker-Preuss M, Mehnert I, Gilman E, et al. · Pract Lab Med · 2021
- Thyroglobulin immunoassay with a fully automated pretreatment process provides accurate thyroglobulin values in anti-thyroglobulin antibody positive specimens.
Kitamura Y, Narita S, Yagi S, et al. · Clin Biochem · 2023
- Evaluation of the highly sensitive Roche thyroglobulin II assay and establishment of a reference limit for thyroglobulin-negative patient samples.
Rotteveel-de Groot DM, Ross HA, Janssen MJR, et al. · Pract Lab Med · 2016
- Multicentre clinical evaluation of the new highly sensitive Elecsys® thyroglobulin II assay in patients with differentiated thyroid carcinoma.
Trimboli P, Imperiali M, Piccardo A, et al. · Clin Endocrinol (Oxf) · 2018Multicenter Study, Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code MSW.
- Access ThyroglobulinBeckman Coulter, Inc. · 510(k) 2024
- Atellica IM Thyroglobulin (Tg)Siemens Healthcare Diagnostics, Inc. · 510(k) 2025
- Brahms Diagnostica Dynotest Tg-PlusBrahms Diagnostica, LLC · 510(k) 2002
- Nichols Advantage ThyroglobNichols Institute Diagnostics · 510(k) 2000
- Nichols Chemiluminescence Thyroglobulin, Model 60-4240Nichols Institute Diagnostics · 510(k) 2000
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.